TMED2-DT

Across TCGA pan-cancer cohorts, TMED2-DT RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TMED2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where TMED2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMED2-DT is over-expressed in tumor.

COAD, BLCA, and HNSC are the cancer types where TMED2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMED2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+0.501	<.001	11	view →
BLCA	Female	III,IV	+0.497	<.001	11	view →
HNSC	Male	III,IV	+0.284	<.001	10	view →
LIHC	Male	III,IV	+0.447	<.001	9	view →
LUSC	All	II,III,IV	+0.441	<.001	8	view →
LUAD	Male	All	+0.421	<.001	7	view →
STAD	All	II,III,IV	+0.396	<.001	6	view →
BRCA	All	II,III,IV	+0.172	.002	6	view →
CHOL	Male	All	+1.308	<.001	5	view →
READ	All	All	+0.407	<.001	5	view →
KIRC	All	All	+0.129	.004	5	view →
KIRP	All	IV	+0.585	.014	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TMED2-DT–COAD

Open the COAD breakdown →